Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
| Autor: | Keret, Shiri, Henig, Israel, Zuckerman, Tsila, Kaly, Lisa, Shouval, Aniela, Awisat, Abid, Rosner, Itzhak, Rozenbaum, Michael, Boulman, Nina, Lazar, Ariela Dortort, Molad, Yair, Sabbah, Firas, Naffaa, Mohammad E, Hardak, Emilia, Slobodin, Gleb, Rimar, Doron |
|---|---|
| Předmět: |
HEMATOPOIETIC stem cell transplantation
VITAL capacity (Respiration) PULMONARY gas exchange PATIENT safety ANTINEOPLASTIC agents MYCOPHENOLIC acid RITUXIMAB HOMOGRAFTS RETROSPECTIVE studies DESCRIPTIVE statistics SYSTEMIC scleroderma HEALTH outcome assessment PROGRESSION-free survival PATIENT aftercare THERAPEUTICS |
| Zdroj: | Rheumatology; Jun2024, Vol. 63 Issue 6, p1534-1538, 5p |
| Abstrakt: | Objectives Autologous hematopoietic stem cell transplantation (AHSCT) has been shown to improve long-term survival for early diffuse progressive SSc compared with CYC. CYC, however, does not provide a long-term benefit in SSc. The combination of MMF and rituximab is a potent alternative regimen. We aimed to retrospectively compare the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab. Methods Repeated assessments of modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), and diffusing capacity (DLCO) values were conducted. Clinical improvement was defined as an mRSS decrease >25% or an FVC increase >10%. Event-free survival (EFS) was defined in the absence of persistent major organ failure or death. Results Twenty-one SSc patients in the combination therapy group were compared with 16 in the AHSCT group. Age, sex and disease duration were similar between the two groups. Clinical improvement at 12 months was seen in 18 (86%) patients in the combination group compared with 13 (81%) in the AHSCT group (P = 0.7). The hazard ratio for EFS at 24 months favoured the combination group (HR = 0.09, P = 0.04). During follow-up, both groups exhibited a significant and comparable reduction in mRSS and an increase in FVC values at each time interval up to 24 months. Conclusion MMF and rituximab compared with AHSCT in SSc patients eligible for AHSCT resulted in similar skin and lung clinical improvement with a better safety profile at 24 months. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|